TAMPA, Fla. (Dec. 19, 2025) — A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease ...

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed ...

Accelerating the Future of Oncology Drug Development: The Role of Consortia in the Delivery of Precision Oncology Early Phase Clinical Trials ASCO Guidelines provide recommendations with comprehensive ...

Germline testing is a genetic screening that looks for inherited gene mutations found in every cell.  It can identify ...

A new Moffitt Cancer Center study suggests a widely used genomic test can more accurately identify which men with early prostate cancer are at high risk for their disease to come back quickly after ...

A new study using serial liquid biopsies to track how metastatic prostate cancer evolves under treatment pressure showed that ...

MiraDx, a molecular diagnostics company focused on genetic testing to personalize cancer treatment, today announced the U.S. commercial launch of PROSTOX™ Standard, a new, clinically validated genetic ...

Prostate cancer screening saves many more lives than earlier studies suggested, research shows. The results from the longest-running European trial show one life saved for every six men diagnosed, a ...